Affiliations
AffiliationItem in Clipboard
Effectiveness of Lung Cancer Screening Implementation in the Community Setting in the United StatesAmy Copeland et al. J Oncol Pract. 2019 Jul.
. 2019 Jul;15(7):e607-e615. doi: 10.1200/JOP.18.00788. Epub 2019 May 31. AffiliationItem in Clipboard
AbstractPurpose: The National Lung Screening Trial demonstrated a 20% relative reduction in lung cancer mortality with low-dose computed tomography screening, leading to implementation of lung cancer screening across the United States. The Centers for Medicare and Medicaid Services approved coverage, but questions remained about effectiveness of community-based screening. To assess screening implementation during the first full year of CMS coverage, we surveyed a nationwide network of lung cancer screening centers, comparing results from academic and nonacademic centers.
Methods: One hundred sixty-five lung cancer screening centers that have been designated Screening Centers of Excellence responded to a survey about their 2016 program data and practices. The survey included 21 pretested, closed- and open-ended quantitative and qualitative questions covering implementation, workflow, numbers of screening tests completed, and cancers diagnosed.
Results: Centers were predominantly community based (62%), with broad geographic distribution. In both community and academic centers, more than half of lung cancers were diagnosed at stage I or limited stage, demonstrating a clear stage shift compared with historical data. Lung-RADS results were also comparable. There are wide variations in the ways centers address Centers for Medicare and Medicaid Services requirements. The most significant barriers to screening implementation were insurance and billing issues, lack of provider referral, lack of patient awareness, and internal workflow challenges.
Conclusion: These data validate that responsible screening can take place in a community setting and that lung cancers detected by low-dose computed tomography screening are often diagnosed at an early, more treatable stage. Lung cancer screening programs have developed different ways to address requirements, but many implementation challenges remain.
FiguresFig 1.
A snapshot of lung cancer…
Fig 1.
A snapshot of lung cancer screening in the United States, 2016. (A) Geographic…
Fig 1.A snapshot of lung cancer screening in the United States, 2016. (A) Geographic distribution of the 165 Screening Centers of Excellence survey respondents. (B) Screening Centers of Excellence reported if they had an academic or university affiliation. (C) Time of initiation of each screening program and relationship to US Preventive Services Task Force (USPSTF) recommendation and Centers for Medicare and Medicaid Services (CMS) national coverage determination.
Fig 2.
Implementation of Centers for Medicare…
Fig 2.
Implementation of Centers for Medicare and Medicaid Services (CMS) requirements. (A) Provider who…
Fig 2.Implementation of Centers for Medicare and Medicaid Services (CMS) requirements. (A) Provider who performs shared decision-making counseling. (B) Smoking cessation resources provided to current smokers. Centers could choose multiple responses if applicable. (C) Information on whether screening centers follow up with current smokers after cessation counseling. PCP, primary care physician.
Fig 3.
Lung cancer screening results. (A)…
Fig 3.
Lung cancer screening results. (A) Lung Imaging Reporting and Data System (Lung-RADS) score…
Fig 3.Lung cancer screening results. (A) Lung Imaging Reporting and Data System (Lung-RADS) score distribution category from more than 40,000 low-dose computed tomography scans (n = 24,249 nonacademic centers; n = 16,186 academic-affiliated centers). (B) Percentage of each stage and type of lung cancer diagnosed at nonacademic centers (n = 272 cancer diagnoses at baseline screen; n = 59 diagnoses at annual screen) compared with academic-affiliated centers (n = 151 cancer diagnoses at baseline; n = 47 cancer diagnoses at annual screen). NSCLC, non–small cell lung cancer; SCLC, small-cell lung cancer.
Similar articlesNemesure B, Plank A, Reagan L, Albano D, Reiter M, Bilfinger TV. Nemesure B, et al. J Med Screen. 2017 Dec;24(4):208-213. doi: 10.1177/0969141316689111. Epub 2017 Feb 15. J Med Screen. 2017. PMID: 28201949
Roth JA, Sullivan SD, Goulart BH, Ravelo A, Sanderson JC, Ramsey SD. Roth JA, et al. J Oncol Pract. 2015 Jul;11(4):267-72. doi: 10.1200/JOP.2014.002600. Epub 2015 May 5. J Oncol Pract. 2015. PMID: 25943596 Free PMC article.
Begnaud A, Hall T, Allen T. Begnaud A, et al. Am Soc Clin Oncol Educ Book. 2016;35:e468-75. doi: 10.1200/EDBK_159195. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249755
Fintelmann FJ, Bernheim A, Digumarthy SR, Lennes IT, Kalra MK, Gilman MD, Sharma A, Flores EJ, Muse VV, Shepard JA. Fintelmann FJ, et al. Radiographics. 2015 Nov-Dec;35(7):1893-908. doi: 10.1148/rg.2015150079. Epub 2015 Oct 23. Radiographics. 2015. PMID: 26495797 Review.
Jokerst C, Oliva I, Mohammed TL. Jokerst C, et al. Curr Probl Diagn Radiol. 2015 Mar-Apr;44(2):113-7. doi: 10.1067/j.cpradiol.2014.08.002. Epub 2014 Dec 23. Curr Probl Diagn Radiol. 2015. PMID: 25541106 Review.
Zheng Q, Zhang J, Wang X, Zhang W, Xiao Y, Hu S, Xu J. Zheng Q, et al. Onco Targets Ther. 2021 Jan 15;14:469-479. doi: 10.2147/OTT.S269300. eCollection 2021. Onco Targets Ther. 2021. PMID: 33488101 Free PMC article.
Trendowski MR, Lusk CM, Wenzlaff AS, Neslund-Dudas C, Gadgeel SM, Soubani AO, Schwartz AG. Trendowski MR, et al. Cancer Epidemiol Biomarkers Prev. 2023 Nov 1;32(11):1558-1563. doi: 10.1158/1055-9965.EPI-23-0174. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 37578347 Free PMC article.
Rivera MP, Katki HA, Tanner NT, Triplette M, Sakoda LC, Wiener RS, Cardarelli R, Carter-Harris L, Crothers K, Fathi JT, Ford ME, Smith R, Winn RA, Wisnivesky JP, Henderson LM, Aldrich MC. Rivera MP, et al. Am J Respir Crit Care Med. 2020 Oct 1;202(7):e95-e112. doi: 10.1164/rccm.202008-3053ST. Am J Respir Crit Care Med. 2020. PMID: 33000953 Free PMC article.
Sedani AE, Davis OC, Clifton SC, Campbell JE, Chou AF. Sedani AE, et al. J Natl Cancer Inst. 2022 Nov 14;114(11):1449-1467. doi: 10.1093/jnci/djac154. J Natl Cancer Inst. 2022. PMID: 35993616 Free PMC article.
Vonder M, Dorrius MD, Vliegenthart R. Vonder M, et al. Transl Lung Cancer Res. 2021 Feb;10(2):1154-1164. doi: 10.21037/tlcr-20-808. Transl Lung Cancer Res. 2021. PMID: 33718053 Free PMC article. Review.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3